Xtx Topco LTD Neurocrine Biosciences Inc Transaction History

Xtx Topco LTD

$1.13 Billion
Q4 2024

A detailed history of Xtx Topco LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Xtx Topco LTD holds 6,866 shares of NBIX stock, worth $768,442. This represents 0.08% of its overall portfolio holdings.

Number of Shares

6,866

Previous 8,665 20.76%

Holding current value

$768,442

Previous $997,000 6.02%

% of portfolio

0.08%

Previous 0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$111.62 - $139.44 $200,804 - $250,852	-1,799 Reduced 20.76%	6,866 $937,000
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $609,794 - $815,064	5,322 Added 159.2%	8,665 $997,000
Q2 2024 Aug 12, 2024	SELL	$130.86 - $143.19 $584,159 - $639,200	-4,464 Reduced 57.18%	3,343 $460,000
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $435,796 - $480,379	3,342 Added 74.85%	7,807 $1.08 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $127,283 - $159,312	1,200 Added 36.75%	4,465 $588,000
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $492,946 - $613,955	-5,243 Reduced 61.62%	3,265 $367,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $365,282 - $427,869	4,080 Added 92.14%	8,508 $802,000
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $1,788 - $2,337	19 Added 0.43%	4,428 $448,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $149,621 - $178,138	1,402 Added 46.62%	4,409 $526,000
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $46,659 - $54,659	-507 Reduced 14.43%	3,007 $319,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $266,326 - $351,645	3,514 New	3,514 $343,000

Others Institutions Holding NBIX

# of Institutions

656

Shares Held

96.6M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account